Physician profile
Erin Ramsay
NPI 1063920429
$6,093.15
in general payments reported to CMS, 2019-2025
33 companies · $1,698 in 2025
The $1,698 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $718 · 2023: $1,524 · 2024: $1,753 · 2025: $1,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,915 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,914.50 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,237.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $685.98 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $621.39 | 2021-2025 | |
| Amgen INC. | $455.18 | 2023-2025 | Repatha, Otezla, Repatha |
| Gilead Sciences, INC. | $450.25 | 2024-2025 | Descovy |
| Lilly USA, LLC | $375.09 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $344.05 | 2023-2025 | Wegovy, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $321.87 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $318.18 | 2021-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $140.02 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Merck Sharp & Dohme LLC | $135.81 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Edwards Lifesciences Corporation | $105.09 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.66 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $94.84 | 2021-2025 | Spravato |
| Inogen, INC. | $73.65 | 2023-2025 | Inogen |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $58.38 | 2021-2022 | |
| Exact Sciences Corporation | $53.90 | 2025 | Cologuard Collection Kit |
| Amneal Pharmaceuticals LLC | $52.48 | 2024-2025 | Unithroid |
| Idorsia Pharmaceuticals US INC | $50.22 | 2022-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $48.92 | 2022 | |
| Axsome Therapeutics, INC. | $44.30 | 2025 | Symbravo |
| Avanir Pharmaceuticals, INC. | $44.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.06 | 2022-2023 | |
| Lucid Diagnostics INC. | $36.54 | 2021-2022 | |
| Eisai INC. | $34.15 | 2021 | |
| Sanofi Pasteur INC. | $28.79 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $24.38 | 2021 | |
| Dexcom, INC. | $23.50 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $22.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.20 | 2023 | |
| Amarin Pharma, INC. | $16.54 | 2021 | |
| Sumitomo Pharma America, INC. | $16.15 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Ramsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.